Nasdaq Biotechnology Ishares (IBB) 231.50 $IBB
iShares Nasdaq Biotechnology Index Fund (IBB) : Short Sell @ $226.44
Trading Central - Thu May 15, 10:33AM CDT
From a technical view, the ETF is shaping a symmetrical triangle calling for the continuation of the previous bearish trend. Regarding technical indicators, the daily MACD is facing a strong resistance area while the daily RSI is reversing down from...
R.I.P. the Momentum Trade, 2012-2014
at The Street - Tue May 13, 1:39PM CDT
The momentum trade is dead. And a new momentum trade has risen to take its place.
iShares Nasdaq Biotechnology Index Fund (IBB) : Close former position at last price ($232.50)
Trading Central - Tue May 13, 9:10AM CDT
On a relative basis against the IVV S&P500, the iShares Nasdaq Biotechnology Index Fund is losing upward momentum since it is reversing down from a bearish trend line; we prefer to close our long position opened on April 22nd. Trading strategy: ...
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.42% Yesterday
Comtex SmarTrend(R) - Mon May 12, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.42% Rise
Comtex SmarTrend(R) - Mon May 12, 4:03PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Growth Correction Over - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon May 12, 2:00PM CDT
Where are you finding GARP now?
Market Bulls Gather for Investors Rotating Portfolios
at The Street - Mon May 12, 12:04PM CDT
Despite all the recent divergences, the market is setting up for a bullish week.
Premier Biomedical Advances Technology via Partnerships
ACCESSWIRE - Fri May 09, 9:28AM CDT
Whitefish, MT / May 9, 2014 / Biotechnology stocks have had a rough quarter, with the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) falling more than 6% since February. Investors have started to re-evaluate the sector's lofty valuations, while higher interest rates in the near future could slow the M&A frenzy. As a result, investors may want to shift their attention to high-growth bargains in the industry.
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.82%
Comtex SmarTrend(R) - Thu May 08, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.82%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 08, 3:49PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure.
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
iShares Nasdaq Biotechnology Index Fund (IBB) : Short Sell @ $226.44
Trading Central - Thu May 15, 10:33AM CDT
From a technical view, the ETF is shaping a symmetrical triangle calling for the continuation of the previous bearish trend. Regarding technical indicators, the daily MACD is facing a strong resistance area while the daily RSI is reversing down from...
R.I.P. the Momentum Trade, 2012-2014
at The Street - Tue May 13, 1:39PM CDT
The momentum trade is dead. And a new momentum trade has risen to take its place.
iShares Nasdaq Biotechnology Index Fund (IBB) : Close former position at last price ($232.50)
Trading Central - Tue May 13, 9:10AM CDT
On a relative basis against the IVV S&P500, the iShares Nasdaq Biotechnology Index Fund is losing upward momentum since it is reversing down from a bearish trend line; we prefer to close our long position opened on April 22nd. Trading strategy: ...
Watch for iShares Nasdaq Biotechnology Index to Potentially Pullback After Gaining 2.42% Yesterday
Comtex SmarTrend(R) - Mon May 12, 4:06PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Pullback after Yesterday's 2.42% Rise
Comtex SmarTrend(R) - Mon May 12, 4:03PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $227.09 to a high of $232.40. Yesterday, the shares gained 2.4%, which took the trading range above the 3-day high of $231.14 on volume of 1.8 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Growth Correction Over - Real Time Insight
Kevin Cook - Zacks Investment Research - Mon May 12, 2:00PM CDT
Where are you finding GARP now?
Market Bulls Gather for Investors Rotating Portfolios
at The Street - Mon May 12, 12:04PM CDT
Despite all the recent divergences, the market is setting up for a bullish week.
Premier Biomedical Advances Technology via Partnerships
ACCESSWIRE - Fri May 09, 9:28AM CDT
Whitefish, MT / May 9, 2014 / Biotechnology stocks have had a rough quarter, with the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) falling more than 6% since February. Investors have started to re-evaluate the sector's lofty valuations, while higher interest rates in the near future could slow the M&A frenzy. As a result, investors may want to shift their attention to high-growth bargains in the industry.
iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.82%
Comtex SmarTrend(R) - Thu May 08, 3:50PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
After Yesterday's Decline of 1.82%, iShares Nasdaq Biotechnology Index Offers Investors Better Value
Comtex SmarTrend(R) - Thu May 08, 3:49PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $222.87 to a high of $231.14. Yesterday, the shares fell 1.8%, which took the trading range below the 3-day low of $223.00 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
Kevin Cook - Zacks Investment Research - Mon May 05, 1:49AM CDT
Bull of the Day: Gilead Sciences (GILD) - Bull of the Day
'Fast Money' Recap: The Problem With Growth Stocks
at The Street - Tue Apr 29, 4:00AM CDT
The trading panel wonders why Facebook is having a good quarter when Google has been selling off.
Pharma ETFs: A Safe Haven from the Biotech Stock Slump? - ETF News And Commentary
Eric Dutram - Zacks Investment Research - Mon Apr 28, 10:42AM CDT
Why investors may want to think about a play on the pharmaceutical ETFs if they want drug industry exposure.
iShares Nasdaq Biotechnology Index Falls 2.46% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of iShares Nasdaq Biotechnology Index After 2.46% Loss
Comtex SmarTrend(R) - Fri Apr 25, 3:55PM CDT
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $223.43 to a high of $229.28. Yesterday, the shares fell 2.5%, which took the trading range below the 3-day low of $223.61 on volume of 2.7 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Celgene Beats on First-Quarter Earnings: What's Next?
George Budwell, The Motley Fool - Motley Fool - Thu Apr 24, 1:30PM CDT
Source: www.fiercepharma.com. Celgene Corporation is the second-largest component of the iShares Nasdaq Biotech Index . As such, its 14% plus nosedive year to date has undoubtedly played a role in driving this key biotech index lower for...
Earnings from Gilead and Amgen Put These ETFs in Focus - ETF News And Commentary
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 7:00AM CDT
Solid results from Gilead, but poor results from Amgen, look to have a big impact on these health care ETFs.
